BioMarin Pharmaceutical Inc. provided financial guidance for 2023. For the period, the company expects Total Revenues to be $2,375 million to $2,500 million. GAAP Net Income $155 million to $205 million.
GAAP Diluted EPS $0.78 to $1.03.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
74.43 USD | -1.44% | -3.40% | -22.81% |
BioMarin Pharmaceutical Inc. provided financial guidance for 2023. For the period, the company expects Total Revenues to be $2,375 million to $2,500 million. GAAP Net Income $155 million to $205 million.
GAAP Diluted EPS $0.78 to $1.03.
1st Jan change | Capi. | |
---|---|---|
-22.81% | 14.34B | |
-1.64% | 90.28B | |
-1.97% | 39.5B | |
-15.47% | 31.71B | |
+61.28% | 26.41B | |
-8.82% | 12.89B | |
-11.77% | 11.8B | |
-45.97% | 10.95B | |
+3.30% | 8.85B | |
-13.92% | 7.53B |